Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.35 |
| ▸ | AADAT | Q8N5Z0 | 4/20 | 0.32 |
| ▸ | CPT1A | P50416 | 8/20 | 0.31 |
| ▸ | CPT2 | P23786 | 7/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.31 |
| ▸ | CPS1 | P31327 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6466361 | 0.91 | TRPV1 (0.34) | TRPV1AADATCPT1ACPT2PKM | |
| SCHEMBL6468793 | 0.91 | TRPV1 (0.35) | TRPV1AADATCPT1ACPT2PKM | |
| SCHEMBL6468514 | 0.89 | TRPV1 (0.34) | TRPV1AADATCPT1ACPT2PKM | |
| SCHEMBL6466357 | 0.89 | TRPV1 (0.38) | TRPV1AADATCPT1ACPT2PKM | |
| SCHEMBL6466217 | 0.88 | BACE1 (0.36) | TRPV1AADATCPT1ACPT2PKM | |
| SCHEMBL2728770 | 0.88 | BACE1 (0.36) | TRPV1AADATCPT1ACPT2PKM | |
| SCHEMBL2725976 | 0.87 | TRPV1 (0.36) | TRPV1AADATCPT1ACPT2PKM | |
| SCHEMBL6465338 | 0.87 | TRPV1 (0.36) | TRPV1AADATCPT1ACPT2PKM | |
| SCHEMBL2727050 | 0.87 | TRPV1 (0.36) | TRPV1AADATCPT1ACPT2PKM | |
| SCHEMBL6468856 | 0.86 | BACE1 (0.34) | TRPV1AADATCPT1ACPT2CPT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012054510-A1 | OXADIAZOLE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |